Psoriasis | Emerging Therapies | Tremfya (IL-23) (guselkumab) | Wave 3 | US | 2018
In the past decade, TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen), as well as Janssen’s IL-12/23 inhibitor Stelara, have been leading the U.S. psoriasis biologics market. However, the recent wave of U.S. approvals for novel psoriasis agents—Celgene’s Otezla (2014), Novartis’s Cosentyx (2015), Eli Lilly’s Taltz (2016), Valeant’s Siliq (2017), Janssen’s Tremfya (2017), and Sun Pharma’s Ilumya (2018)—is anticipated to substantially alter the market landscape. The Psoriasis Emerging Therapy series includes three waves that will track the awareness, trial, and use of Tremfya following its launch in July 2017 for the treatment of psoriasis. In addition, the series will examine physicians’ anticipation of future trends in psoriasis treatment, particularly Tremfya’s uptake, and assess Janssen’s promotional efforts.
Questions Answered:
- What is the awareness of, familiarity with, and perceptions related to Tremfya among U.S. dermatologists?
- According to prescribers, to which patients are they prescribing Tremfya, why are they prescribing Tremfya, and how satisfied are they with Tremfya?
- How do prescribers and nonprescribers compare across key metrics?
- How is the trial and adoption of Tremfya tracking compared with other recent product launches in the autoimmune market?
Product Description:
Emerging Therapies is a three-wave series based on primary research data collected at 1, 6, and 12 months postcommercial launch with U.S. physicians. The research captures physicians’ awareness, perceptions, and use of the launched product, as well as anticipated future trends. Insight is also provided on promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other launched agents.
